US-based immuno-oncology company Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as Bavencio by its original developer Merck KgaA (Merck), as a combination therapy in non-small cell lung cancer (NSCLC).
Operated in collaboration with Merck’s Swiss subsidiary Ares Trading, the Phase I/II study (NCT05267626) is investigating Aulos Bioscience’s AU-007 as a combination therapy for second-line treatment.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The announcement follows after Aulos and Merck disclose a collaboration and supply agreement, which saw the former provided with the rights to use the treatment as part of its efforts to address cancer care through best-in-class interleukin-2 (IL-2) therapeutics.
The third and final part of the Phase I/II trial is evaluating avelumab in combination with AU-007 and low-dose, subcutaneous aldesleukin, an IL-2 therapy. Avelumab is described as a human anti-programmed death ligand-1 (PD-L1) antibody approved for use in multiple tumour types.
Aulos say that pre-clinical results detail strong anti-cancer activity, including complete tumour eradication, from AU-007 and a single loading dose of human IL-2 and an anti-PD-L1 surrogate of avelumab.
The Phase I/II study is currently enrolling patients with unresectable locally advanced or metastatic cancer at multiple clinical trial site locations in the US and Australia.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPreviously, the company has announced positive Phase I and preliminary Phase II data from the trial at the Society for Immunotherapy of Cancer (SITC) 39th annual meeting. This data showed AU-007 and low-dose, subcutaneous aldesleukin to be clinically active in tackling melanoma.
Aulos Bioscience CEO Aron Knickerbocker said: “We are excited to move forward with evaluating this combination therapy in a clinical setting after seeing encouraging synergy with AU-007 and a surrogate model of avelumab in preclinical studies including complete elimination of established solid tumours.
“Avelumab’s profile, coupled with AU-007 and low-dose, subcutaneous aldesleukin, could potentially offer a new therapeutic option for patients with advanced or metastatic PD-L1+ non-small cell lung cancer that has progressed following first-line therapy with a checkpoint inhibitor,” Knickerbocker added.
Elsewhere in treatments utilising avelumab, Transgene’s stock has dropped after a Phase II trial of its therapeutic vaccine candidate TG4001 (tipapkinogene sovacivec) in combination with avelumab failed to meet its primary endpoint of improvement in progression-free survival (PFS) in solid tumours.
Meanwhile, Immutep has received approval from the Paul-Ehrlich-Institut (PEI), German Federal Institute for Vaccines and Biomedicines, to start its INSIGHT-005 Phase I trial of eftilagimod alpha (efti), along with avelumab for the treatment of metastatic urothelial carcinoma.
